SCHEMBL16755446

SCHEMBL16755446

COC(=O)c1ccc2c(c1)nc(NC(=O)c1cccc(C(F)(F)F)c1)n2-c1cccc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.62
MAP3K7 O43318 3/20 0.51
IRAK4 Q9NWZ3 3/20 0.51
IRAK1 P51617 2/20 0.51
MAPT P10636 2/20 0.46
EPHB4 P54760 2/20 0.45
RXFP1 Q9HBX9 2/20 0.43
LCK P06239 2/20 0.42
ALDH1A1 P00352 1/20 0.42
TEC P42680 1/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
BRAF P15056 1/20 0.42
INSR P06213 1/20 0.42
LYN P07948 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16767967 0.90 EGFR (0.61) EGFRMAP3K7IRAK4IRAK1MAPT
SCHEMBL16767958 0.88 EGFR (0.61) EGFRMAP3K7IRAK4IRAK1MAPT
SCHEMBL16767966 0.86 EGFR (0.60) EGFRMAP3K7IRAK4IRAK1MAPT
SCHEMBL16770023 0.86 EGFR (0.58) EGFRMAP3K7IRAK4IRAK1MAPT
SCHEMBL16755394 0.80 THRB (0.43) MAPTALDH1A1RAB9AKMT2A
SCHEMBL16767960 0.79 EGFR (0.57) EGFRRXFP1ALDH1A1TECMEN1
SCHEMBL20985290 0.78 EGFR (0.67) EGFRMAP3K7IRAK4IRAK1MAPT
SCHEMBL13500556 0.77 MAP3K7 (0.69) EGFRMAP3K7IRAK4IRAK1EPHB4
SCHEMBL16755416 0.76 EGFR (1.00) EGFRMAP3K7IRAK4IRAK1TEC
SCHEMBL20985384 0.76 EGFR (0.66) EGFRMAP3K7IRAK4IRAK1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152083-A1 Compounds and Compositions for Modulating EGFR Activity IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-06-04 US disclosed
US-20150152083-A1 Compounds and Compositions for Modulating EGFR Activity IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-06-04 US disclosed
US-20150152083-A1 Compounds and Compositions for Modulating EGFR Activity IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152083-A1 Compounds and Compositions for Modulating EGFR Activity EGFR, ERBB2, ERBB3 EGFR 1/4885MAP3K7 183/4885IRAK4 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.